Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) EBT Margin (2021 - 2024)

Goldenwell Biotech filings provide 4 years of EBT Margin readings, the most recent being 43015.82% for Q4 2024.

  • On a quarterly basis, EBT Margin fell 3501621.0% to 43015.82% in Q4 2024 year-over-year; TTM through Sep 2025 was 12900.63%, a 1838759.0% increase, with the full-year FY2024 number at 94602.88%, down 8821067.0% from a year prior.
  • EBT Margin hit 43015.82% in Q4 2024 for Goldenwell Biotech, down from 35913.67% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 10.49% in Q3 2022 to a low of 43015.82% in Q4 2024.
  • Median EBT Margin over the past 4 years was 5181.45% (2023), compared with a mean of 10035.23%.
  • Biggest five-year swings in EBT Margin: surged 604653bps in 2023 and later plummeted -3501621bps in 2024.
  • Goldenwell Biotech's EBT Margin stood at 602.28% in 2021, then skyrocketed by 98bps to 10.49% in 2022, then tumbled by -76144bps to 7999.62% in 2023, then plummeted by -438bps to 43015.82% in 2024.
  • The last three reported values for EBT Margin were 43015.82% (Q4 2024), 35913.67% (Q2 2024), and 7999.62% (Q4 2023) per Business Quant data.